Methods of using and compositions including an incretin analog
AssigneeEli Lilly and Company
InventorsTamer COSKUN, Zvonko MILICEVIC, Shweta URVA
Life of this patent
Estimating the term…
Abstract
Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.
Claims22
-94. (canceled)
A method of treating a condition, disease or disorder in an individual having a body mass index (BMI) of ≥27 kg/m2, the method comprising:
- administering to the individual a first once weekly dose of a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist comprising a structure of SEQ ID NO:1, wherein the first once weekly dose is about 2.0 mg and is administered for at least 1 week;
- and
- increasing the first once weekly dose by increments of about 1.0 mg to about 4.0 mg to a once weekly dose of ≤12.0 mg, wherein each increased once weekly dose is administered for at least 1 week;
- and
- wherein the condition, disease or disorder is obstructive sleep apnea (OSA), osteoarthritis (OA), chronic kidney disease (CKD) and/or cardiovascular (CV) disease.
A method of treating a condition, disease or disorder in an individual having a body mass index (BMI) of ≥27 kg/m2, the method comprising the steps of:
- (a) administering to the individual about 2.0 mg of a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist comprising a structure of SEQ ID NO:1 for at least 1 week;
- (b) administering to the individual about 4.0 mg of the GGG tri-receptor agonist for at least 1 week;
- and
- (c) administering to the individual about 6.0 mg of the GGG tri-receptor agonist weekly for at least 1 week;
- wherein the condition, disease or disorder is obstructive sleep apnea (OSA), osteoarthritis (OA), chronic kidney disease (CKD) and/or cardiovascular (CV) disease.
Dependencies are inferred from the claim text.